Ranolazine and late cardiac sodium current – a therapeutic target for angina, arrhythmia and more?

    loading  Checking for direct PDF access through Ovid


Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.

Related Topics

    loading  Loading Related Articles